Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $1.18, 55% below $2.63, its close on the day of its Oct 16 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$2.5MCash on Hand
2.3mo Cash Runway
Follow MEDS by emailGet an email when MEDS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MEDS, unsubscribe in one click. Privacy
📣 What MEDS Says Is Next
Second Half 2026 · “Interim co-CEO Gerald Commissiong featured on Fox Business together with NFL Legend Emmitt Smith to discuss NFLAH support for Health Lives Here Expected Remaining Second Half 2026 Milestones”
Company press release, Aug 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Deal DataMEDS AI terminated its October 19, 2026 Second Amended and Restated Letter of Intent with Datavault AI, REBOOT Health AI, EOS Technology, Scilex and HealthBridge Advisors, citing market conditions. The company says no fees are owed and no shares will be issued under it. Form 8-K · SEC filing · Press release
Oct 26, 2026 ·
Deal DataMEDS signed a non-binding Second A&R LOI on Oct 19, 2026, to acquire QLPM IP from EOS and Scilex, expand its Datavault AI license, and take a controlling interest in Tollo Health. Target post-closing ownership: 89.5% held by counterparties. Definitive agreements are pending. Form 8-K · SEC filing · Press release
Oct 20, 2026 ·
Listing DataMeds AI received a Nasdaq notice dated October 19, 2026 confirming it regained compliance with the $2.5 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1). The company had reported stockholders' equity of $(12,447,801) in its 2025 annual report. Form 8-K · SEC filing · Press release
Oct 16, 2026 ·
Deal DataMeds signed an exclusive US license with REBOOT Health AI for GLP-1 direct-to-consumer use, issuing 666,667 shares plus a $50,000 payment and revenue sharing. Nasdaq flagged stockholders' equity of $(12,447,801) and the company is converting debt into stock. Form 8-K · SEC filing
Oct 13, 2026 ·
Deal DataMEDS AI confirmed stockholders' equity above $2,500,000. It settled litigation with Norton and others for $450,000, repurchasing 364,099 shares and extinguishing about $19 million in liability. It also licensed a care management platform from REBOOT Health AI, issuing 666,667 shares. Form 8-K · SEC filing
Sep 17, 2026 ·
Legal Settled litigation with Brian Norton, Nomad Capital, Strategix Global and others over the May 2023 MIPA and shares. The company paid $450,000, including $350,000 to repurchase and extinguish 364,099 common shares, and expects to extinguish about $19 million in balance sheet liability. Form 8-K · SEC filing
Sep 16, 2026 ·
Deal DataMeds AI acquired Helomics Corporation from Axe Compute for 636,328 common shares, about 19.99% of shares outstanding, plus a $1,363,672 convertible note at a $1.00 conversion price. The press release cites $1.5 million in cash received. Form 8-K · SEC filing · Press release
Aug 18, 2026 ·
Earnings DataMeds AI reported Q2 2026 revenue of $1.779M, up 14% from Q1, and a net operating loss of $18.363M versus $6.672M a year earlier. Net loss per share was $7.13. The 8-K furnishes the earnings press release as Exhibit 99.1. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
MEDS holds $2.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations,
an estimated runway of 2.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 2 months +40
Shelf registration (S-3, Apr 2026) +10
Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern within twelve months from the date these unaudited condensed consolidated financial statements are issued.10-Q, Aug 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 3,061,919 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MEDS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.